Sugi Predict

Sugi Predict / Compounds / SCHEMBL496136

SCHEMBL496136

SCHEMBL496136

CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)[C@@H]1CO1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.54
▸ CTSS P25774 3/20 0.52
▸ CTSK P43235 2/20 0.52
▸ CTSL P07711 1/20 0.52
▸ CTSB P07858 1/20 0.52
▸ ACE P12821 2/20 0.50
▸ KLK5 Q9Y337 4/20 0.48
▸ KLK7 P49862 4/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865405 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL2079109 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL4974304 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL2983027 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL7438571 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL1104909 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL2983024 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
SCHEMBL639229 1.00 ATM (0.54) ATMCTSSCTSKCTSLCTSB
Butylbenzyl SCHEMBL8490527 0.91 CTSK (0.50) ATMCTSSCTSKCTSLCTSB
Butylbenzyl SCHEMBL8487457 0.91 CTSK (0.50) ATMCTSSCTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6764545-B2 ADDING WATER TO A SOLUTION OF THE EPOXIDE CRYSTAL, (2R,3S) OR (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-1,2-EPOXY-4-PHENYLBUTANE IN A POLAR SOLVENT TO ALLOW CRYSTALLIZATION; COMPOUND IS AN HIV PROTEASE INHIBITOR INTERMEDIATE AJINOMOTO CO., INC. (JP) 2004-07-20 — — US claimed
EP-1346979-A1 PROCESSES FOR PREPARATION OF N-PROTECTED- -AMINO ALCOHOLS AND N-PROTECTED- -AMINO EPOXIDES Ajinomoto Co., Inc. (JP) 2003-09-24 — — EP claimed
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 — — US disclosed
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2022-10-06 — — US disclosed
CN-115038688-A USP30 inhibitors and uses thereof 文森雷生物科学股份有限公司 2022-09-09 — — CN disclosed
EP-4028385-A1 USP30 INHIBITORS AND USES THEREOF Vincere Biosciences, Inc. (US) 2022-07-20 — — EP disclosed
EP-1910317-B1 1-AMINO LINKED COMPOUNDS LILLY CO ELI (US) 2013-07-03 — — EP disclosed
EP-1910317-B1 1-AMINO LINKED COMPOUNDS LILLY CO ELI (US) 2013-07-03 — — EP disclosed
US-8283346-B2 Human immunodeficiency virus protease inhibitors THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (US) 2012-10-09 — — US disclosed
US-8283346-B2 Human immunodeficiency virus protease inhibitors THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (US) 2012-10-09 — — US disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 — — US disclosed
US-20110112068-A1 HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY 2011-05-12 — — US disclosed
US-20110112068-A1 HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY 2011-05-12 — — US disclosed
US-20090312318-A1 THERAPEUTIC COMPOUNDS AND METHODS GILEAD SCIENCES, INC. 2009-12-17 — — US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 — — US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 — — US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 — — US disclosed
US-20080070910-A1 Therapeutic compounds and methods GILEAD SCIENCES, INC. 2008-03-20 — — US disclosed
WO-2008013834-A1 BISFURANYL PROTEASE INHIBITORS GILEAD SCIENCES, INC., (US) 2008-01-31 — — WO disclosed
EP-1346979-A1 PROCESSES FOR PREPARATION OF N-PROTECTED- -AMINO ALCOHOLS AND N-PROTECTED- -AMINO EPOXIDES Ajinomoto Co., Inc. (JP) 2003-09-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 ATM 4603/4885CTSS 1095/4885CTSK 2012/4885
US-20110112068-A1 HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS SERPINB1, PREP, TMPRSS15 ATM 4234/4885CTSS 65/4885CTSK 120/4885
US-20090312318-A1 THERAPEUTIC COMPOUNDS AND METHODS SERPINB1, ABCC1, SERPINB6 ATM 3215/4885CTSS 50/4885CTSK 34/4885
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ATM 1438/4885CTSS 2213/4885CTSK 2165/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ATM 1438/4885CTSS 2213/4885CTSK 2165/4885
US-20080070910-A1 Therapeutic compounds and methods SERPINB1, ABCC1, SERPINB6 ATM 3215/4885CTSS 50/4885CTSK 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.